Fisetin Side Effects

Reported Fisetin side effects

Fisetin has a highly favorable safety profile in both preclinical and emerging clinical data, with minimal serious adverse events reported at typical supplementation doses and acceptable tolerability at high pulse-dose senolytic protocols. Gastrointestinal tolerance: generally excellent. Mild transient nausea, loose stools, or gastric discomfort at high doses (1000+ mg per dose) in a minority of users. Taking with food eliminates most complaints. Dividing a pulse dose (e.g., 1500 mg split into morning and evening doses on pulse days) reduces GI complaints compared to single bolus dosing. Headache: uncommon, typically mild and transient when reported. Usually occurs at initiation of high-dose supplementation and resolves within 24-48 hours. Orange-yellow urine discoloration: occasional at high doses due to excretion of fisetin metabolites. Harmless and resolves with reduced intake. Fatigue: some users report transient fatigue on senolytic pulse-dosing days, potentially reflecting the biological activity of senescent cell clearance. Usually mild and resolves 1-3 days after completing the pulse. Flushing: rare, transient, typically during initial pulse-dose exposure. Paresthesia (tingling): extremely rare. Reversible on dose reduction. Drug interactions — fewer clinically significant than quercetin but still warrant attention: Tyrosine kinase inhibitor chemotherapy (dasatinib, imatinib, erlotinib, gefitinib): fisetin has intrinsic tyrosine kinase modulation and may produce unintended additive effects. The intentional D+Q combination with dasatinib is clinically relevant for senolytic applications; other combinations require oncology specialist supervision. Warfarin and anticoagulants: fisetin has mild antiplatelet activity and potential CYP2C9 modulation. Effect is smaller than for quercetin. Monitor INR when initiating fisetin supplementation during warfarin therapy. Fluoroquinolone antibiotics: fisetin binds DNA gyrase at the same binding site as fluoroquinolones, potentially antagonizing antibacterial activity. Separate doses by 2-4 hours or avoid during active fluoroquinolone therapy. Some CYP3A4-metabolized drugs: fisetin may modestly inhibit CYP3A4. Clinically significant interactions are uncommon at typical doses but possible at pulse-dosing senolytic levels (1000+ mg per dose). Review medication list. P-glycoprotein substrates (digoxin, some chemotherapy agents): potential modest interaction through P-gp inhibition. Monitor if both are required. Chemotherapy agents generally: oncology patients should discuss fisetin supplementation with their oncologist. The mTOR-inhibitory and autophagy-inducing effects have theoretical implications for chemotherapy synergy or antagonism. Antihypertensive medications: fisetin has modest cardiovascular effects; monitor blood pressure when initiating, though clinically significant interactions are rare. Iron supplementation: chelation reduces iron absorption. Separate by 2-4 hours if both are being actively supplemented. Pregnancy: human safety data at supplementation doses are limited. Dietary intake through strawberries and other natural sources is unambiguously safe. High-dose supplementation during pregnancy is generally avoided in the absence of specific medical indication. Lactation: limited data. Dietary intake is safe. Supplementation data are limited. Pediatric use: not indicated for routine use in healthy children. Specific pediatric conditions (neurodegenerative syndromes, childhood cancer adjunct) may warrant supplementation under specialist supervision. Senolytic pulse-dosing safety considerations: At the AFFIRM-LITE protocol of 20 mg/kg for 2 consecutive days monthly, pilot human data show the protocol is well-tolerated with no dose-limiting toxicity. Mild transient fatigue, GI effects, or headache on pulse days are the most commonly reported. The intermittent nature of senolytic pulses minimizes cumulative exposure and allows tissue recovery between pulses. At very high doses (3000+ mg daily for multiple consecutive days), the safety profile is less well-characterized. Conservative practice uses the AFFIRM-LITE-style protocol (20 mg/kg for 2 consecutive days monthly) rather than higher or more sustained dosing. Liver function: not associated with fisetin at any tested dose. No consistent signal of liver enzyme elevation. Renal function: not associated with fisetin. No specific renal dose adjustment. Patients with severe CKD stage 4-5 may warrant dose reduction in the absence of specific PK data in that population. Cardiovascular: fisetin has modest favorable effects on endothelial function and blood pressure. No arrhythmogenic concerns. Patients with severe cardiovascular disease should discuss supplementation with their cardiologist. Hematologic: mild antiplatelet activity is present but less pronounced than for aspirin or prescription antiplatelets. Discontinue 2 weeks before scheduled surgery as a precaution. Hormone-sensitive cancers: fisetin has weak phytoestrogenic activity. Theoretical caution in active estrogen-sensitive cancers; dietary intake is acceptable; specialist consultation warranted before high-dose or pulse-dose supplementation. Autoimmune disease: fisetin's anti-inflammatory and immune-modulating effects are generally favorable. No specific contraindications in most autoimmune conditions. Surgery: the antiplatelet effect warrants discontinuation 2 weeks before scheduled surgery to minimize bleeding risk. Extremely high-dose research protocols: fisetin has been tested up to 500 mg/kg in mice with good tolerability. Human scaling has been conservative, with pulse doses at 20 mg/kg the most commonly used protocol and continuous dosing typically limited to 100-500 mg daily. Allergic reactions: fisetin itself is not a common allergen. Strawberry-derived fisetin supplements are rare (most commercial fisetin is from Rhus or synthetic) so strawberry allergy is not typically a concern. Supplement excipients (capsule materials, fillers) may cause reactions in sensitive individuals. Long-term safety: animal studies in aged mice up to 10 months of intermittent pulse dosing have not identified safety concerns. Human long-term data from AFFIRM-LITE and subsequent trials are still accumulating but early signals are favorable. Overall, fisetin supplementation at doses of 100-500 mg daily continuously or 20 mg/kg for 2 consecutive days monthly (approximately 1400-1600 mg for an average adult) is well-tolerated in most users. The main practical considerations are drug interactions (anticoagulants, fluoroquinolones, tyrosine kinase inhibitors, chemotherapy), surgical bleeding risk, and the theoretical need for specialist supervision in oncology and complex medication contexts. The risk-benefit profile is favorable for most adult users interested in senolytic or longevity-focused supplementation.

When to continue, reduce, or stop Fisetin

Fisetin contraindications

Contraindications for fisetin supplementation are generally relative rather than absolute, with favorable safety across both continuous maintenance dosing and intermittent pulse-dose protocols. Absolute contraindications: None established in typical adults at standard supplementation doses. Fisetin has an exceptionally favorable safety profile in preclinical and clinical studies. Relative contraindications and caution situations: Tyrosine kinase inhibitor chemotherapy (non-senolytic context) — fisetin has intrinsic tyrosine kinase modulation. The intentional D+Q combination with dasatinib for senolytic purposes is clinically recognized; other combinations require oncology specialist supervision. Warfarin anticoagulation — fisetin has mild antiplatelet activity and potential CYP2C9 modulation (less pronounced than quercetin). Monitor INR at 1-2 weeks after starting fisetin or after initiating pulse-dose protocol. Fluoroquinolone antibiotics — potential antagonism of antibacterial activity. Separate doses by 2-4 hours or suspend fisetin during active fluoroquinolone therapy. Chemotherapy agents — fisetin's mTOR inhibition, autophagy induction, and P-glycoprotein modulation may affect chemotherapy exposure or efficacy. Oncology specialist required. CYP3A4-metabolized drugs at high pulse doses — possible interactions with statins, some antihypertensives, and some protease inhibitors. Usually not clinically significant at typical maintenance doses but review at pulse-dose levels. P-glycoprotein substrates (digoxin, some chemotherapy) — potential modest increase in exposure through P-gp inhibition. Monitor if both are required. Antiplatelet medications (aspirin, clopidogrel) — additive bleeding risk; usually not clinically significant at standard doses. Pregnancy — dietary intake through strawberries and other natural sources is unambiguously safe. Supplementation at maintenance or pulse doses during pregnancy has limited safety data. Conservative practice is to rely on dietary intake and avoid supplementation during pregnancy without specific medical indication. Lactation — limited data at supplementation doses. Dietary intake is safe. Pediatric use — not routinely indicated for healthy children. Specific pediatric indications (neurodegenerative syndromes, certain cancer adjunct contexts) may warrant supplementation under specialist supervision. Hepatic impairment — conjugation is reduced in severe liver disease potentially altering pharmacokinetics. No established hepatotoxicity. Use moderate doses and monitor clinical response. Renal impairment — no specific renal toxicity. Severe CKD (stage 4-5) may warrant dose reduction due to altered clearance and lack of specific PK data in this population. Active peptic ulcer disease — the mild antiplatelet effect may warrant caution in the presence of bleeding ulcer. Usually not a significant clinical concern but avoid during active GI bleeding contexts. Hormone-sensitive cancers — fisetin has weak phytoestrogenic activity (less than quercetin). Theoretical caution exists in active estrogen-sensitive cancers. Specialist consultation warranted before high-dose or pulse-dose supplementation in this context. Surgery — the antiplatelet effect warrants discontinuation 2 weeks before scheduled surgery to minimize bleeding risk. Resume after surgical recovery. Severe or uncontrolled hypertension — fisetin has modest blood pressure effects. Monitor but usually not a contraindication. Extremely high-dose protocols (beyond 20 mg/kg for 2 days monthly) — long-term safety at doses exceeding the AFFIRM-LITE reference is less characterized. Conservative practice is to use established dosing protocols rather than improvising higher doses. Recent stroke or bleeding disorder — the mild antiplatelet effect may warrant caution. Coordinate with neurology or hematology. Strawberry allergy — most commercial fisetin is extracted from Rhus succedanea or Acacia, not strawberries. Strawberry allergy is not typically a concern for fisetin supplementation. Synthetic fisetin is also available. Known allergy to supplement excipients — capsule materials, fillers, or phytosome lecithin components may cause reactions in sensitive individuals. Specific clinical situations warranting specialist guidance: Active cancer or recent chemotherapy — coordinate with oncology. Solid organ transplant recipients — coordinate with transplant team; immunosuppressive drug interactions may occur. Multiple medications with CYP3A4 or P-gp involvement — review interaction potential before adding fisetin. Pregnancy and fertility treatment — avoid supplementation; dietary intake safe. Severe renal or hepatic impairment — reduce dose and monitor clinical response. Bleeding disorders or current anticoagulation — coordinate with hematology. Overall, fisetin supplementation at continuous maintenance doses of 100-200 mg daily or intermittent pulse doses of 20 mg/kg for 2 consecutive days monthly in most adults has a favorable risk-benefit profile. The main practical considerations are drug interactions (anticoagulants, tyrosine kinase inhibitor chemotherapy, fluoroquinolones), surgical bleeding risk, limited pregnancy data, and the need for specialist supervision in oncology and complex medication contexts. The D+Q combination with prescription dasatinib requires specialist medical supervision and is not self-administered.

Why vendor quality drives Fisetin side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Fisetin side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .